Hennion & Walsh Asset Management Inc. Makes New $1.74 Million Investment in Fulgent Genetics, Inc. $FLGT

Key Points

• Hennion & Walsh Asset Management bought a new stake of 66,190 shares in Fulgent Genetics (NASDAQ:FLGT), valued at about $1.74 million and representing roughly 0.21% of the company at quarter-end.
• Fulgent beat quarterly EPS estimates ($0.16 vs. $0.02) but remains unprofitable (negative net margin and ROE) and issued FY2026 EPS guidance around -1.45; analysts’ consensus rating is a Hold with an average target of $32.00.
• Shares opened at $16.44 (12‑month range $13.46–$31.04), trading below both the 50‑day ($20.13) and 200‑day ($23.79) moving averages, and institutional investors own about 48.06% of the stock.

Hennion & Walsh Asset Management Inc. acquired a new stake in Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 66,190 shares of the company's stock, valued at approximately $1,739,000. Hennion & Walsh Asset Management Inc. owned about 0.21% of Fulgent Genetics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of FLGT. Rhumbline Advisers grew its stake in shares of Fulgent Genetics by 2.4% during the second quarter. Rhumbline Advisers now owns 33,139 shares of the company's stock worth $659,000 after purchasing an additional 785 shares in the last quarter. Mackenzie Financial Corp raised its stake in Fulgent Genetics by 11.2% in the third quarter. Mackenzie Financial Corp now owns 12,155 shares of the company's stock valued at $275,000 after buying an additional 1,220 shares in the last quarter. Peapod Lane Capital LLC raised its stake in Fulgent Genetics by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 164,579 shares of the company's stock valued at $3,720,000 after buying an additional 1,810 shares in the last quarter. BNP Paribas Financial Markets lifted its holdings in Fulgent Genetics by 2.5% during the 2nd quarter. BNP Paribas Financial Markets now owns 87,318 shares of the company's stock worth $1,736,000 after buying an additional 2,128 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Fulgent Genetics during the 2nd quarter worth about $49,000. 48.06% of the stock is currently owned by institutional investors and hedge funds.

Fulgent Genetics Trading Up 3.4%

Shares of FLGT opened at $16.44 on Thursday. The company's 50 day simple moving average is $20.13 and its 200-day simple moving average is $23.79. The firm has a market cap of $513.42 million, a PE ratio of -8.39 and a beta of 0.89. Fulgent Genetics, Inc. has a 12-month low of $13.46 and a 12-month high of $31.04.

Fulgent Genetics (NASDAQ:FLGT - Get Free Report) last released its quarterly earnings results on Friday, February 27th. The company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.02 by $0.14. Fulgent Genetics had a negative net margin of 18.75% and a negative return on equity of 2.22%. The firm had revenue of $83.34 million during the quarter, compared to the consensus estimate of $85.38 million. Fulgent Genetics has set its FY 2026 guidance at -1.450--1.450 EPS. As a group, equities research analysts forecast that Fulgent Genetics, Inc. will post -0.85 EPS for the current fiscal year.

Analysts Set New Price Targets

FLGT has been the topic of a number of recent analyst reports. Wall Street Zen downgraded Fulgent Genetics from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Zacks Research cut Fulgent Genetics from a "strong-buy" rating to a "hold" rating in a research note on Monday, February 9th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Fulgent Genetics in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $32.00.

About Fulgent Genetics

Fulgent Genetics, Inc NASDAQ: FLGT is a California-based company specializing in high-complexity genetic testing and diagnostic services. Operating from its headquarters in Temple City, Fulgent leverages next-generation sequencing (NGS) technologies and advanced bioinformatics to deliver a broad range of clinical and research assays. The company's infrastructure includes CAP- and CLIA-certified laboratories, enabling it to process large volumes of samples with rapid turnaround times.

Fulgent's product portfolio encompasses hereditary cancer panels, rare disease and neuromuscular disorder testing, pharmacogenomic screenings, non-invasive prenatal tests, and infectious disease assays including COVID-19 diagnostics.

Want to see what other hedge funds are holding FLGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fulgent Genetics, Inc. (NASDAQ:FLGT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.